Literature DB >> 9369264

Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes.

K Yamamoto1, U Ikeda, K Okada, T Saito, Y Kawahara, M Okuda, M Yokoyama, K Shimada.   

Abstract

We investigated the effects of arginine vasopressin (AVP) on nitric oxide (NO) synthase activity in cardiac myocytes by measuring the production of nitrite, a stable metabolite of NO, and the expression of inducible NO synthase (iNOS) mRNA and protein. Incubation of cultured neonatal rat cardiac myocytes for 24 hours with interleukin-1beta (IL-1beta) caused a significant increase in NO production. Both AVP and V1a receptor agonist [Phe2,Ile3,Orn8]vasopressin augmented NO synthesis in IL-1beta-stimulated, but not in unstimulated myocytes, in a dose-dependent manner. The V1a receptor antagonist [d(CH2)[5]1,O-Me-Tyr2,Arg8]vasopressin completely inhibited the effect of AVP. The AVP-induced NO production by IL-1beta-stimulated cells was accompanied by increased iNOS mRNA and protein accumulation. AVP caused a significant increase in cytosolic free Ca2+ levels of cardiac myocytes, whereas it showed no effect on cytosolic cAMP levels. After protein kinase C activity was functionally depleted by treating cells with phorbol 12-myristate 13-acetate for 24 hours, AVP did not augment IL-1beta-induced NO production. The effect of AVP was also inhibited in the presence of the protein kinase C inhibitor calphostin C. The addition of AVP increased protein kinase C activity in cardiac myocytes, and its effect was significantly inhibited in the presence of calphostin C. These results support the hypothesis that the heart may be a target organ for AVP and that AVP modulates IL-1beta-induced iNOS expression in myocytes through the V1a receptor, which is mediated at least partially via activation of protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369264     DOI: 10.1161/01.hyp.30.5.1112

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  4 in total

Review 1.  A global perspective on vasoactive agents in shock.

Authors:  Djillali Annane; Lamia Ouanes-Besbes; Daniel de Backer; Bin DU; Anthony C Gordon; Glenn Hernández; Keith M Olsen; Tiffany M Osborn; Sandra Peake; James A Russell; Sergio Zanotti Cavazzoni
Journal:  Intensive Care Med       Date:  2018-06-04       Impact factor: 17.440

Review 2.  Vasopressor therapy in critically ill patients with shock.

Authors:  James A Russell
Journal:  Intensive Care Med       Date:  2019-10-23       Impact factor: 17.440

3.  Oxytocin-Gly-Lys-Arg: a novel cardiomyogenic peptide.

Authors:  Bogdan A Danalache; Jolanta Gutkowska; Magdalena J Slusarz; Irena Berezowska; Marek Jankowski
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

Review 4.  Arginine vasopressin receptor signaling and functional outcomes in heart failure.

Authors:  Melissa A Wasilewski; Valerie D Myers; Fabio A Recchia; Arthur M Feldman; Douglas G Tilley
Journal:  Cell Signal       Date:  2015-07-30       Impact factor: 4.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.